First Trust NYSE Arca Biotech Index Fd

Jefferies, JPMorgan, and Barclays Issue Ratings for Illumina Stock

Illumina's Chief Legal Officer Sells Shares

Natera Inc Official Discloses Stock Ownership Change

Natera Director Herm Rosenman Disposed of Common Stock

Jefferies analyst reiterates buy rating on Natera with a target price of $275

Natera Inc. Announces Improvement in Early High-Risk Breast Cancer Recurrence Risk Assessment with Signatera™ ctDNA Test

Squarepoint Ops LLC Reduces Stake in Brook

Armstrong Henry H Associates Inc. reduced holdings in Waters Corp.

JPMorgan Raises Illumina's Target Price to $130

Illumina and MyOme Partner to Advance Genomic Sequencing with AI

Nikko Asset Management Increases Stake in Illumina by 28.8%

Morgan Stanley Raises Regeneron Pharmaceuticals Target Price

Stanley Druckenmiller's Dukus Family Office Increases Stake in Natera Inc.

Akorda Pharma Receives FDA Approval for DAYBUE STIX

Natera Inc. and MEDSIR Initiate Clinical Trial for HR+/HER2- Breast Cancer

Waters Corp Underperformed Market with 9.4% CAGR Over Five Years

Regeneron Vice President Marion McCourt Sells Shares to Pay Taxes

BMO Capital and Truist Financial Maintain Buy Rating for Regeneron Pharmaceuticals

Illumina Inc. partners with MyOme to advance AI-based genomic health solutions

Wells Fargo Analyst Maintains Hold Rating on Regeneron Pharmaceuticals

Mega Fortune

Processa Pharmaceuticals

cbdMD

Agape ATP

VYNE Therapeutics

Inspirato

Andersen

Medline Inc.

Creative Global Tech

GCI LIBERTY INC COM USD0.01 SER C SUBS RTS 17/12/2025

INCY

Shares of Incyte rise 1.9% after the European Commission approves expanded use of its cancer drug Minjuvi for treating relapsed or refractory follicular lymphoma. Minjuvi was already approved for diffuse large B-cell lymphoma. Stock up 42.2% YTD.

Reuters

Incyte

BUZZ-Incyte up after European Commission expands use of cancer drug

REGN

Woodstock Corp increased its stake in Regeneron Pharmaceuticals by 107.1% in Q3, owning 16,610 shares worth $9,339,000. Other investors also adjusted their positions in REGN. Insider sales included Director Christine A. Poon and VP Jason Pitofsky. Analysts issued new price targets, with a consensus rating of "Moderate Buy" and an average price target of $779.45. REGN stock opened at $746.36, with a 12-month low of $476.49 and high of $790.98.

Market Beat

Regeneron Pharma

Woodstock Corp Acquires 8,589 Shares of Regeneron Pharmaceuticals, Inc. $REGN

AVTR

ILMN

Jefferies updates ratings for life sciences firms for 2026. Maintains "buy" for Waters, Neogenomics, and Danaher Corp, citing growth prospects. Downgrades Avantor to "underperform" due to structural challenges. Reiterates "hold" for Illumina amid uncertainties. Adjusted price targets: Waters $470, Neogenomics $15, Avantor $9, Danaher Corp $255, Illumina $125.

Avantor

Danaher

Illumina

BUZZ-Jefferies updates ratings on life sciences firms for 2026

Jefferies has maintained a Hold rating for Illumina (ILMN) with a price target of $125.00. Additionally, J.P. Morgan's Casey Woodring also issued a Hold rating, while Barclays maintained a Sell rating for the same stock. These ratings reflect varying investment research opinions on Illumina's market position.

Tip Ranks

Jefferies Sticks to Its Hold Rating for Illumina (ILMN)

Incyte announced that the European Commission has approved Minjuvi® (tafasitamab) in combination with lenalidomide and rituximab for treating relapsed or refractory follicular lymphoma (FL) in adults. This approval provides a new chemotherapy-free option for FL patients in Europe, addressing a critical need. The decision is based on positive results from the Phase 3 inMIND trial, showing significant improvement in progression-free survival. Minjuvi is the first CD19- and CD20-dual-targeted immunotherapy approved for this condition in Europe.

StockTitan

Incyte Announces European Commission Approval of Minjuvi® (tafasitamab) for the Treatment of Relapsed or Refractory Follicular Lymphoma | INCY Stock News

Regeneron Pharmaceuticals' stock has surged recently, raising questions about its valuation. Despite the rise, analyses suggest the stock is undervalued. A Discounted Cash Flow model estimates its intrinsic value at $1,592.76 per share, indicating a 53.1% discount compared to the market price of $746. Additionally, its PE ratio is below industry averages, further supporting undervaluation. Investors are encouraged to consider Regeneron's growth potential and valuation metrics for investment decisions.

Simplywall

Is Regeneron Still Attractively Priced After Its Recent Share Price Surge?

NTRA

Officer Moshkevich Solomon of Natera Inc (NTRA) filed a Form 4 with the SEC on December 16, 2025, disclosing changes in ownership. Transactions include exercising 22,376 shares at $9.59, surrendering 4,692 shares at $230.76, and gifting 295 shares. Ending holdings are 126,450 shares directly.

Natera

Officer Moshkevich Acquires 17,684 Of Natera Inc [NTRA]

Rosenman Herman Director of Natera Inc [NTRA] filed a Form 4 on December 16, 2025 with the Securities and Exchange Commission disclosing the following changes in ownership:Date12/12/25TransactionSaleShares48,419Price$227.42Value$11,011,478Ending Holdings: 20,342 - DirectFor a free trial, or to learn more about our insider trading analysis and data services, please visit or contact us at (301) 913-5100 or send an email to info@washingtonservice.com.Founded in 1970, The Washington Service provides securities professionals with financial, economic and public policy research and data.

Dir Rosenman Sells 48,419 ($11M) Of Natera Inc [NTRA]

Scott M Davies, Chief Legal Officer of Illumina, sold 323 shares worth $43,957 on December 16, 2025. Despite this insider activity, TipRanks' AI Analyst rates ILMN as 'Outperform' due to strong earnings and positive technical indicators, though valuation concerns and cash flow challenges exist. Illumina's YTD price performance is 3.05%, with a market cap of $20.61B.

Top Exec Sells Illumina Shares in a Surprising Move!

Herm Rosenman, Director of Natera Inc., has reported the disposal of common shares of the company. This information was published by Natera Inc. via the EDGAR system on December 16, 2025. The news is generated by Public Technologies using AI and is for informational purposes only.

Natera Inc. Director Herm Rosenman Reports Disposal of Common Shares

Shares of Illumina Inc. (ILMN) fell 2.49% to $131.56 on Tuesday, underperforming compared to competitors Labcorp Holdings Inc. (LH), Charles River Laboratories International Inc. (CRL), and Quest Diagnostics Inc. (DGX). The S&P 500 Index fell 0.24% and the Dow Jones Industrial Average fell 0.62%. Illumina Inc. is 14.05% below its 52-week high of $153.06 reached on January 14th.

Dow Jones

Illumina Inc. Stock Underperforms Tuesday When Compared To Competitors

BIIB

Biogen Inc.'s stock fell 2.41% to $171.50 on Tuesday, underperforming compared to competitors like Johnson & Johnson, Pfizer, and AbbVie. The stock's decline ended a two-day winning streak and was part of a broader market downturn, with the S&P 500 and Dow Jones also falling. Biogen's trading volume exceeded its 50-day average, and the stock remains 7.38% below its 52-week high.

Biogen

Biogen Inc. Stock Underperforms Tuesday When Compared To Competitors

A $1000 investment in Natera (NASDAQ:NTRA) 10 years ago would now be worth $19,654.28, reflecting an annualized return of 35.12%, outperforming the market by 22.32%. Natera's current market cap is $31.71 billion. This highlights the impact of compounded returns on investment growth over time.

benzinga_article

Here's How Much $1000 Invested In Natera 10 Years Ago Would Be Worth Today

PRIM

LYFT

Primoris, Lyft, and Incyte are three overlooked stocks that could double by 2026. Each company is experiencing improving economics, identifiable catalysts, and undervalued valuations. Primoris focuses on infrastructure projects, Lyft is enhancing its unit economics and exploring autonomous driving partnerships, and Incyte is diversifying its oncology and immunology platform. The potential for these stocks to double lies in market perception shifts and execution of strategic plans.

Forbes

Primoris

Three Over Looked StocksThat Could Double In 2026